Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT00300222Phase 3Completed
Phase 3, randomised, double-blind trial of capsaicin in postherpetic neuralgia (PHN) (2 arms), sponsored by NeurogesX. Primary endpoint: Percent change from baseline in average pain for the past 24 hours NPRS score (Weeks 2 to 12) at 12 weeks. Started Mar 2006; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT00300222.